阿托伐他汀钙致糖代谢异常大鼠模型的建立-东南大学学报医学版

阿托伐他汀钙致糖代谢异常大鼠模型的建立

作者：林燕珊 ¹ 朱孔博 ² 钱玲林 ² 安丽 ¹ 慕广建 ¹ 任利群 ¹ 2

单位：1. 东南大学附属中大医院老年医学科, 江苏南京 210009;
2. 东南大学附属中大医院

关键词：阿托伐他汀钙血糖胰岛素动物模型大鼠

分类号：R587.1

出版年·卷·期（页码）：2018·37·第六期（1028-1032）

摘要：

目的：建立阿托伐他汀钙致糖代谢异常大鼠模型。方法：将16只健康雄性Wistar大鼠随机分为对照组和阿托伐他汀钙组，阿托伐他汀钙组大鼠给予阿托伐他汀钙50 mg·kg^-1·d^-1灌胃，对照组大鼠给予等体积去离子水灌胃。两组干预24周后行口服葡萄糖耐量试验和胰岛素释放试验，计算胰岛β细胞功能指数（HOMA-β）、胰岛素抵抗指数（HOMA-IR）及胰岛素敏感指数（HOMA-IS），检测血生化指标并行胰腺组织的病理学检查。结果：与对照组比较，口服葡萄糖耐量试验显示阿托伐他汀钙组30、60、90和120 min的血糖均明显升高（P<0.05）；胰岛素释放试验显示阿托伐他汀钙组空腹、30、60、90和120 min胰岛素分泌水平均降低（P<0.05），HOMA-β和HOMA-IR降低，而HOMA-IS升高（均P<0.05）；光镜下观察两组胰腺病理组织形态均无明显异常改变。结论：采用大剂量阿托伐他汀钙长时程干预可成功建立他汀致糖代谢异常大鼠模型。

Objective:To explore the method of establishing rats model with abnormal glucose metabolism induced by atorvastatin calcium. Methods:Sixteen healthy male Wistar rats were randomly divided into two groups:the control group (n=8) and the atorvastatin calcium group (n=8).Rats in the atorvastatin calcium group were given atorvastatin calcium (50 mg·kg^-1·d^-1) by intragastric administration and in the control group were given an equal volume deionized water for 24 weeks. Then an oral glucose tolerance test and measures of insulin release were performed. HOMA-β, HOMA-IR and HOMA-IS were calculated.The blood biochemical parameters and pathology of pancreas were also examined.Results:At 30, 60, 90 and 120 min after glucose intake, the blood glucose levels of the atorvastatin calcium group were all significantly higher than those of the control group(P<0.05).The serum insulin levels before and 30, 60, 90, 120 min after glucose intake in the atorvastatin calcium group were all significantly lower than those in the control group(P<0.05). HOMA-β and HOMA-IR decreased significantly, while the HOMA-IS increased significantly in the atorvastatin calcium group (all P<0.05). No significant differences were found in the pathology of pancreas under an optical microscope between the two groups. Conclusion:Rats model with abnormal glucose metabolism can be successfully established by long term treatment with high dose of atorvastatin calcium.

参考文献：

[1] CATAPANO A L,GRAHAM I,de BACKER G,et al.2016 ESC/EAS Guidelines for the management of dyslipidaemias[J].Eur Heart J,2016,37(39):2999-3058.
[2] ROFFI M,PATRONO C,COLLET J P,et al.2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the european society of cardiology (ESC)[J].Eur Heart J,2016,37(3):267-315.
[3] RIDKER P M,DANIELSON E,FONSECA F A,et al.Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein[J].N Engl J Med,2008,359(21):2195-2207.
[4] SATTAR N,PREISS D,MURRAY H M,et al.Statins and risk of incident diabetes:a collaborative meta-analysis of randomised statin trials[J].Lancet,2010,375(9716):735-742.
[5] ERQOU S,LEE C C,ADLER A I.Statins and glycaemic control in individuals with diabetes:a systematic review and meta-analysis[J].Diabetologia,2014,57(12):2444-2452.
[6] PREISS D,SESHASAI S R,WELSH P,et al.Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy:a meta-analysis[J].JAMA,2011,305(24):2556-2564.
[7] WATERS D D,HO J E,DEMICCO D A,et al.Predictors of new-onset diabetes in patients treated with atorvastatin:results from 3 large randomized clinical trials[J].J Am Coll Cardiol,2011,57(14):1535-1545.
[8] SALUNKHE V A,ELVSTAM O,ELIASSON L,et al.Rosuvastatin treatment affects both basal and glucose-induced insulin secretion in INS-1832/13 Cells[J].PLoS One,2016,11(3):e0151592.
[9] YALURI N,MODI S,LÍPEZ RODRÍGUEZ M,et al.Simvastatin impairs insulin secretion by multiple mechanisms in MIN6 cells[J].PLoS One,2015,10(11):e0142902.
[10] SADIGHARA M,JOKTAJI J P,HAJHASHEMI V,et al.Protective effects of coenzyme Q10 and L-carnitine against statin-induced pancreatic mitochondrial toxicity in rats[J].Res Pharm Sci,2017,12(6):434-443.
[11] KANDA M,SATOH K,ICHIHARA K.Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin[J].Biol Pharm Bull,2003,26(12):1681-1684.
[12] BEOWSKI J,ATANASSOVA P,CHALDAKOV G N,et al.Opposite effects of pravastatin and atorvastatin on insulin sensitivity in the rat:role of vitamin D metabolites[J].Atherosclerosis,2011,219(2):526-531.
[13] SASAKI J,IWASHITA M,KONO S.Statins:beneficial or adverse for glucose metabolism[J].J Atheroscler Thromb,2006,13(3):123-129.
[14] CHAPMAN M J,ORSONI A,ROBILLARD P,et al.Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes:insights from the CAPITAIN and PREVAIL-US studies[J].Curr Med Res Opin,2014,30(5):775-784.
[15] CHENG D,WANG Y,GAO S,et al.Atorvastatin delays the glucose clearance rate in hypercholesterolemic rabbits[J].Biomed Pharmacother,2015,72:24-29.
[16] CEDERBERG H,STAN?amp;Aacute;KOVÁ A,YALURI N,et al.Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion:a 6 year follow-up study of the METSIM cohort[J].Diabetologia,2015,58(5):1109-1117.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录